Substituted quinazoline compounds and methods of use thereof
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R 1 , R 2a , R 2b , R 2c , A, B, L 1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
1. A compound having the following structure (I):
or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein:
A is N;
B is oxo, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl, amino, alkylamino, arylamino, —CO 2 H, —CONH 2 , aminylcarbonyl, aminylcarbonylalkyl, heteroarylamino, halo, haloalkyl, alkoxy, haloalkoxy, aryl or —X-L 2 -R a ;
X is —NR b — or —O—;
L 1 is alkylene, cycloalkylene, heterocyclylene or absent;
L 2 is alkylene or absent;
R is H, cyano, amino, halo, haloalkyl, hydroxyl, cycloalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, —CO 2 H, —CONH 2 , aminylcarbonyl, C 1 -C 6 alkyl, C 1 -C 6 alkylaminyl or C 1 -C 6 alkoxy;
R a is cycloalkyl, heterocyclyl, heteroaryl, —(C═O)OH, —(C═O)NH 2 or —(C═O)NHOH;
R b is, at each occurrence, independently H or C 1 -C 6 alkyl;
R 1 is aryl or heteroaryl;
R 2a , R 2b and R 2c are each independently H, amino, cyano, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkylaminyl, —NR b (C═O)R b , C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, heterocyclylalkyl, C 2 -C 6 alkynyl, C 2 -C 6 alkenyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, aminylcarbonyl, heteroaryl or aryl;
is a single bond such that all valences are satisfied; and
E is:
wherein:
Q is —C(═O)—, —C(═NR 8 ′)—, —NR 8 C(═O)—, —S(═O) 2 — or —NR 8 S(═O) 2 —;
R 8 is H, C 1 -C 6 alkyl or hydroxylalkyl;
R 8 ′ is H, —OH, —CN or C 1 -C 6 alkyl; and
R 9 and R 10 are each independently H, halo, cyano, carboxyl, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, aryl, heterocyclyl, heterocyclylalkyl, heteroaryl or hydroxylalkyl.
2. The compound of claim 1 , wherein B is cycloalkyl, heterocyclyl or heteroaryl.
3. The compound of claim 1 , wherein L 1 is alkylene or absent.
4. The compound of claim 1 , wherein B is oxo.
5. The compound of claim 4 , wherein the compound has the following structure (IE):
wherein:
G 1 is CH;
G 2 is N or CH;
R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R 3a and R 3b join to form oxo, a carbocyclic or heterocyclic ring; or R 3a is H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R 3b joins with R 4b to form a carbocyclic or heterocyclic ring;
R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R 4a and R 4b join to form oxo, a carbocyclic or heterocyclic ring; or R 4a is H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R 4b joins with R 3b to form a carbocyclic or heterocyclic ring; and
m 1 and m 2 are each independently 1, 2 or 3.
6. The compound of claim 5 , wherein the compound has one of the following structures (IEa), (IEb), (IEc) or (IEd):
7. The compound of claim 5 , wherein the compound has one of the following structures (IEe), (IEf), (IEg), (IEh), (IEi), (IEj), (IEk) or (IEl):
8. The compound of claim 1 , wherein R 1 is aryl.
9. The compound of claim 8 , wherein R 1 is phenyl or naphthyl.
10. The compound of claim 8 , wherein R 1 is substituted with one or more substituents.
11. The compound of claim 10 , wherein R 1 is substituted with halo, amino, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cyano, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, alkylaminyl, cycloalkyl, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylaminyl, cycloalkylaminyl, aryl, heteroaryl, phosphate, phosphoalkoxy, boronic acid, boronic acid ester, —OC(═O)R or C 1 -C 6 alkylcarbonyloxy, or combinations thereof, wherein R is C 1 -C 6 alkyl.
12. The compound of claim 11 , wherein R 1 is substituted with fluoro, chloro, cyclopropyl, cyclobutyl, hydroxyl, amino, methyl, ethyl, isopropyl, trifluoromethyl or methoxy, or combinations thereof.
13. The compound of claim 8 , wherein R 1 has one of the following structures:
14. The compound of claim 1 , wherein R 1 is heteroaryl.
15. The compound of claim 14 , wherein R 1 has one of the following structures:
16. The compound of claim 1 , wherein R 2c is H.
17. The compound of claim 1 , wherein R 2a and R 2b are each independently halo, haloalkyl, alkyl, amino, hydroxyl or alkoxy.
18. The compound of claim 1 , wherein R 2a is fluoro, chloro or methoxy.
19. The compound of claim 1 , wherein R 2b is chloro, fluoro, amino, hydroxyl or CF 3 .
20. The compound of claim 1 , wherein R is H.
21. The compound of claim 1 , wherein Q is —C(═O)—.
22. The compound of claim 1 , wherein each of R 9 and R 10 are H.
23. The compound of claim 1 , wherein E has one of the following structures:
24. The compound of claim 1 , wherein the compound has one of the following structures:
25. A substantially purified atropisomer of the compound according to claim 1 .
26. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
27. A method for treatment of cancer, the method comprising administering an effective amount of the pharmaceutical composition of claim 26 to a subject in need thereof.
28. A method for regulating activity of a KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS G12C mutant protein with the compound of claim 1 .
29. A method for inhibiting proliferation of a cell population, the method comprising contacting the cell population with the compound of claim 1 .
30. A method for treating a disorder mediated by a KRAS G12C, HRAS G12C or NRAS G12C mutation in a subject in need thereof, the method comprising:
determining if the subject has a KRAS, HRAS or NRAS G12C mutation; and
if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 26 .
31. A method for preparing a labeled KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant with a compound of claim 1 , to result in the labeled KRAS, HRAS or NRAS G12C protein.
32. A method for inhibiting tumor metastasis, the method comprising administering an effective amount of the pharmaceutical composition of claim 26 to a subject in need thereof.